1. Home
  2. SG vs PRME Comparison

SG vs PRME Comparison

Compare SG & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sweetgreen Inc.

SG

Sweetgreen Inc.

HOLD

Current Price

$5.85

Market Cap

641.7M

ML Signal

HOLD

Logo Prime Medicine Inc.

PRME

Prime Medicine Inc.

HOLD

Current Price

$3.04

Market Cap

536.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SG
PRME
Founded
2007
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
641.7M
536.4M
IPO Year
2021
2022

Fundamental Metrics

Financial Performance
Metric
SG
PRME
Price
$5.85
$3.04
Analyst Decision
Hold
Buy
Analyst Count
15
6
Target Price
$8.43
$7.56
AVG Volume (30 Days)
6.5M
2.5M
Earning Date
05-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
18.18
EPS
0.82
N/A
Revenue
$679,474,000.00
$4,632,000.00
Revenue This Year
$7.60
$7.06
Revenue Next Year
$8.45
$47.01
P/E Ratio
$7.17
N/A
Revenue Growth
0.39
55.28
52 Week Low
$4.49
$2.67
52 Week High
$10.63
$6.94

Technical Indicators

Market Signals
Indicator
SG
PRME
Relative Strength Index (RSI) 42.26 45.78
Support Level $5.07 $2.73
Resistance Level $6.12 $3.32
Average True Range (ATR) 0.42 0.18
MACD 0.08 0.02
Stochastic Oscillator 43.09 54.62

Price Performance

Historical Comparison
SG
PRME

About SG Sweetgreen Inc.

Sweetgreen Inc is a mission-driven, next-generation restaurant and lifestyle brand that serves healthy food at scale. Its bold vision is to be as ubiquitous as traditional fast food, but with the transparency and quality that consumers increasingly expect. It is creating plant-forward, seasonal, and earth-friendly meals from fresh ingredients and produce that prioritizes organic, regenerative, and local sourcing. Its menu involves, Kids' meal, salads, sides, local items, Protein Plates, Desserts, Drinks and Others.

About PRME Prime Medicine Inc.

Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.

Share on Social Networks: